Clinical trials: Heart Failure, Unspecified
Fluid Retention Caused by Heart Failure
Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention
Phase II clinical study of HRS-9057 injection in patients with heart failure-induced fluid retention
- Trial name
- NCT07318103
- Testing
- HRS-9057 injection set, 5% Glucose Injection or 0.9% sodium chloride injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Cerebral Hemorrhage, Head Injury
Biomarkers Correlation With Volemia
The purpose of this study is to determine whether the Biomarkers (pro adrenomedullin (MR proADM), pro arginin vasopressin (CT proAVP), pro atrial natriuretic peptid (MR proANP), Pro Endothelin) changes at Day 2, Day 5 and Day 7…
- Conditions
- Cerebral Hemorrhage, Head Injury, Non Traumatic Post Surgery, Poly Trauma Patients Without Heart Failure
- Trial name
- ENVOL (NCT01858675)
- Testing
- Biomarkers, red blood cells and plasma assessment
- Where
- France
- Volunteers
- 66 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
Heart Failure
Model 4296 Left Ventricular (LV) Lead Study
This study is designed to show that a new lead, which paces the left bottom chamber (left ventricle) of the heart, is safe. Using a lead on the left side of the heart has been shown to potentially improve heart failure symptoms.
- Trial name
- 4296 (NCT00927251)
- Testing
- Pacing Lead (Model 4296 LV Lead)
- Where
- 16 sites in Austria, Finland and 6 more
- Volunteers
- 90 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices
The registry is primarily designed to assess outcome, efficacy and residual safety aspects of CRT based on long-term data from an unselected, real-life clinical set-up.
- Trial name
- BIO|STREAM HF (NCT03366545)
- Testing
- Cardiac Resynchronization Therapy (CRT)
- Where
- 114 sites in Australia, Austria and 18 more
- Volunteers
- 3,030 people
- Sponsor
- Biotronik SE & Co. KG
Essential Hypertension, Chronic Stable Angina
Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg
The purpose of this study is to compare the pharmacokinetic characteristics and safety of dilatrend SR capsule 32mg and Dilatrend tablet 25mg in healthy male subjects.
- Conditions
- Essential Hypertension, Chronic Stable Angina, Congestive Heart Failure
- Trial name
- NCT01819870
- Testing
- Dilatrend SR capsule 32mg, Dilatrend IR tablet 25mg
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Tachyarrhythmias, Sudden Cardiac Death
SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients
The purpose of this study is to characterize the chronic performance of the St. Jude Medical SJ4 connector and RV high voltage SJ4 leads.
- Conditions
- Tachyarrhythmias, Sudden Cardiac Death, Heart Failure
- Trial name
- NCT00940888
- Testing
- SJ4 connector and RV high voltage SJ4 lead
- Where
- United States
- Volunteers
- 1,701 people
- Sponsor
- Abbott Medical Devices
Heart Failure
Clinical Evaluation Of The SonR Atrial Lead In Paradym RF Device
Sorin Group has developed a new atrial lead which is under evaluation during this study. The SonR atrial lead presents a new sensor in the tip of the lead and allows a new feature; interventricular (VV) and atrioventricular (AV)…
- Trial name
- NCT01169272
- Testing
- CRT-SonR 9770
- Where
- France
- Volunteers
- 100 people
- Sponsor
- LivaNova
Heart Failure, Ventricular Arrythmia
ASCEND CSP IDE Study
This is a prospective, multi-center, global, single-arm, pivotal investigational study designed to evaluate the safety and effectiveness of the CSP ICD Lead in a subject population indicated for ICD or CRT-D therapy.
- Trial name
- ASCEND CSP IDE (NCT06830746)
- Testing
- LBBAP Implant with a CSP ICD Lead
- Where
- 37 sites in United States, Australia and 8 more
- Volunteers
- 414 people
- Sponsor
- Abbott Medical Devices
Heart Failure
LifeVest Trends Validation Protocol
This study will evaluate the accuracy of data on body position, daily activity, heart rate, 6-minute walk test, and a health survey collected by the wearable cardioverter defibrillator (WCD).
- Trial name
- TRENDS (NCT02149290)
- Testing
- Trends-equipped LifeVest 4000
- Where
- 21 sites in United States, Austria and 1 more
- Volunteers
- 198 people
- Sponsor
- Zoll Medical Corporation
Validation of Oximeter System
Correlation of Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter
The purpose of this study is to establish the accuracy of the non-invasive Mespere Oximeter that estimates venous oxygen saturation.
- Trial name
- NCT01908790
- Testing
- Mespere Venous Oximeter, Avoximeter 4000
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mespere Lifesciences Inc.
Heart Failure
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
The purpose of this open-label study was to collect additional safety information of sacubitril/valsartan and to provide post-trial access to sacubitril/valsartan for the eligible Japanese patients who completed…
- Trial name
- NCT06149104
- Testing
- sacubitril/valsartan
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
End-stage Heart Failure
Mechanical Circulatory Support Korea Post Market Surveillance Study (PMS)
Medtronic is sponsoring this Mechanical Circulatory Support (MCS) Korea Post-Market Surveillance (PMS) to evaluate the safety and performance of the HeartWare Ventricular Assist Device System (HVAD® System) when used in routine…
- Trial name
- NCT04543747
- Testing
- HeartWare Ventricular Assist Device
- Where
- 2 sites in South Korea
- Volunteers
- 77 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Sleep Apnea, Central, Sleep Disordered Breathing
Respicardia, Inc. Pivotal Trial of the remedē System
The primary purpose of this prospective, multicenter, randomized trial is to evaluate the safety and effectiveness of therapy delivered by the remedē® system in subjects with moderate to severe central sleep apnea and optimal…
- Conditions
- Sleep Apnea, Central, Sleep Disordered Breathing, Heart Failure
- Trial name
- NCT01816776
- Testing
- Treatment Group (transvenous stimulation of the phrenic nerve), Control Group (Optimal Medical Therapy)
- Where
- 30 sites in United States, Germany and 1 more
- Volunteers
- 151 people
- Sponsor
- Respicardia, Inc.
Cardiac Failure, Respiratory Failure
A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System:The MOBYBOX Trial
The purpose of this study is to evaluate prospectively the safety and performance of the MOBYBOX System in the veno-arterial configuration in patients with cardiorespiratory failure or in the veno-venous configuration in patients…
- Conditions
- Cardiac Failure, Respiratory Failure, Cardio-Respiratory Failure, Imminent Cardiorespiratory or Respiratory Failure
- Trial name
- NCT04183660
- Testing
- MOBYBOX System
- Where
- 4 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Hemovent GmbH
Heart Failure
Crestor Versus Placebo in Subjects With Heart Failure
The purpose of the study is to investigate if rosuvastatin, added on top of all other medicines prescribed to subjects with symptomatic systolic heart failure, reduces the combined endpoint of cardiovascular death or non-fatal…
- Trial name
- NCT00206310
- Testing
- CRESTOR
- Where
- 375 sites in Belgium, Bulgaria and 19 more
- Volunteers
- 5,013 people
- Sponsor
- AstraZeneca
Bradycardia, Heart Failure
BIO|CONCEPT.Amvia Study
The goal of this exploratory study is to test the preliminary safety and product performance of the new Amvia/Solvia pacemaker family in subjects that require a pacemaker or cardiac resynchronization therapy pacemaker (CRT-P)…
- Trial name
- NCT05610176
- Testing
- Amvia Sky pacemaker or CRT-P device
- Where
- 7 sites in Australia, New Zealand
- Volunteers
- 52 people
- Sponsor
- Biotronik Australia Pty Ltd.
Diabetes Mellitus, Heart Failure
Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction
The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular…
- Trial name
- NCT01440517
- Testing
- Tc99m-Maraciclatide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Heart Failure and Impaired Kidney Function
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event.
- Trial name
- BalanceD-HF (NCT06307652)
- Where
- 852 sites in United States, Argentina and 37 more
- Volunteers
- 3,850 people
- Sponsor
- AstraZeneca
Heart Failure
Leadless Electrocardiogram (ECG) Evaluation Study
The leadless electrocardiogram (LECG) is a new technology incorporated into the Consulta CRT-P to obtain an ECG signal from the Consulta CRT-P similar to a surface ECG obtained from the device programmer (PECG) or an external ECG…
- Trial name
- LECG (NCT01297283)
- Testing
- LECG first, Programmer ECG first
- Where
- France
- Volunteers
- 195 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Cardiovascular Disease, Pulmonary Arterial Hypertension
Effect of BIA 5 1058 on Cardiac Repolarization
The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)
- Conditions
- Cardiovascular Disease, Pulmonary Arterial Hypertension, Heart Failure
- Trial name
- NCT03489005
- Testing
- BIA 5-1058, Moxifloxacin 400 mg
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.